Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 4/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886795 | 1.00 | CTSB (0.45) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL7119177 | 0.95 | CCR3 (0.48) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL3879488 | 0.95 | CCR3 (0.48) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL3881565 | 0.84 | CCR3 (0.57) | CCR3 | |
| SCHEMBL3881197 | 0.84 | CCR3 (0.57) | CCR3 | |
| SCHEMBL3881200 | 0.84 | CCR3 (0.57) | CCR3 | |
| SCHEMBL13867616 | 0.82 | CCR3 (0.38) | CCR3 | |
| SCHEMBL3879491 | 0.81 | CASP3 (0.44) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL13876969 | 0.81 | CASP3 (0.44) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL14392696 | 0.79 | EPHX1 (0.52) | CTSBCTSKCTSSCTSLCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | DELUCCA GEORGE V | 2005-11-24 | — | — | US | disclosed |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003024401-A2 | PIPERIZINONES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | CTSB 2644/4885CTSK 2578/4885CTSS 2447/4885 |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | CTSB 2481/4885CTSK 2434/4885CTSS 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.